Saturday 17 October 2026
Export CNTX’s income statement to Excel — free account
Context Therapeutics Inc.
CNTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 66.7% and free cash flow fell 20.6%, each against the same quarter a year earlier.
0.24
0.00
0.00%
Follow CNTX
Context Therapeutics Inc. (CNTX) P/E ratio
Context Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.2× (June 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.2×
Ten-year median
0.0×
Current reading's percentile
90
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| EVAX Evaxion A/S - Sponsored ADR compare | n/m |
| ESLA Estrella Immunopharma, Inc. compare | n/m |
| CNTX Context Therapeutics Inc. | n/m |
| QNTM Quantum Biopharma Ltd. compare | n/m |
| BYSI BeyondSpring Inc. compare | n/m |
| IMMP Prima BioMed Ltd compare | n/m |
| CYAD Celyad SA compare | n/m |
| KYNB Kyntra Bio Inc compare | 0.1× |
| PLRZ Polyrizon Ltd. compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)